李英鹏，民盟，博士，教授，博士生导师。博士毕业于日本东京理科大学，现任天津中医药大学中药学院药物制剂教研室专任教师。

主要从事中药抗肿瘤制剂的研究工作，主持国家自然科学基金面上、青年项目4项、天津市自然科学基金项目2项；第一或通讯作者在Acta Pharmaceutica Sinica B、Journal of Controlled Release等期刊发表学术论文40余篇，单篇最高影响因子14.8。教学方面，获第四届全国高校教师教学创新大赛天津赛区三等奖；担任“互联网+”全国总决赛评委，指导学生获得全国大学生“药苑论坛”一等奖、天津市“挑战杯”及“互联网+”一、二等奖；主持天津市教改课题1项、校级教改课题1项；副主编、编委参编《高等学校中药学类专业课程思政案例选》《中药药剂学》《药剂学》等多部教材；获学校“青年教学标兵”称号。担任教育部高等学校中药药剂学课程联盟副秘书长，入选天津市“325培养计划”党外人才、天津市“高校中青年骨干创新人才培养计划”131第三层次创新人才、天津市青年后备人才等培养计划等。

联系方式：liyingpeng@tjutcm.edu.cn（天津市静海区团泊新城西区鄱阳湖路10号天津中医药大学远志园）

【科研论文】

[1] Qian R#, Ge J#, Fan N, Sun Z, Zhao C, Sun Y, Li Y*（李英鹏）, Li Y*, Fu H*. Natural Products in Cancer Prevention and Therapy Current Challenges and Future Directions. [J]. Medcomm, 2026;7:e70585（中科院大类1区Top，IF=10.7）

[2] Sun Z#, Ge J#, Fu H#, Chen Z, Zhao C, Li X, Sun Y, Gao Z*, Li Y*, Li Y*（李英鹏）. Immunocyte reprogramming empowers live-cell drug delivery- Mechanistic insights, delivery strategies, and clinical perspectives. [J]. Acta Pharmaceutica Sinica B, 2026;16(1):169-197（中科院大类1区Top，IF=14.6）

[3] Fan N, Zhang Y, Ge Z, Li Y, Miao L, Gao Z, Hou G*, Li Y*, Li Y*（李英鹏）. A safe saponin-based nano-strategy for manganese-mediated STING activation. [J]. Journal of Controlled Release, 388 (2025) 114303（中科院大类1区Top，IF=11.5）

[4] Zhong M#, Li Y#（李英鹏）, Wang H#, Fan N, Chu X, Liu L, Zhao C, Sun Y, Zhang S*, Fu H*. Integrated network pharmacology and experimental validation reveal EGFR/p53/Bcl-2–mediated anti-hepatocellular carcinoma effects of Zedoary Turmeric Oil. [J]. Journal of Ethnopharmacology, 352 (2025) 120241（中科院大类2区，IF=5.4）

[5] Zhang R#, Li Y#, Fu H#, Zhao C, Li X, Wang Y*, Sun Y*, Li Y*（李英鹏）. Nanomedicine strategies for cuproptosis Metabolic reprogramming and tumor immunotherapy. [J]. Acta Pharmaceutica Sinica B, 2025;15(9):4582-4613（中科院大类1区Top，IF=14.6）

[6] Liu L#, Ge J#, Fu H#, Wang J, Chen Y, Sun Y, Zhao C, Li Y*, Li Y*（李英鹏）. A fluorinated prodrug strategy enhances the therapeutic index of nanoparticle-delivered hydrophilic drugs. [J].Colloids Surf B Biointerfaces, 2025,249:114539（中科院大类2区，IF=5.4）

[7] Sun Z#, Fu H#, Zhang R, Wang H, Shen S, Zhao C, Li X, Sun Y*, Li Y*, Li Y*（李英鹏）. Advances in chemically modified HSA as a multifunctional carrier for transforming cancer therapy regimens. [J].Int J Biol Macromol, 2025:141373（中科院大类2区Top，IF=8.2）

[8] Wu Y#, Li J#, Liu L, Chu X, Zhong M, Li H, Zhao C, Fu H, Sun Y*, Li Y*（李英鹏）. Hyaluronic acid nanoparticles for targeted oral delivery of doxorubicin: Lymphatic transport and CD44 engagement. [J].Int J Biol Macromol, 2024,273(Pt 2):133063（中科院大类1区Top，IF=7.7）

[9] Tang M#, Zhang Z#, Wang P#, Zhao F, Miao L, Wang Y, Li Y*（李英鹏）, Li Y*, Gao Z*. Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells. [J].Acta Pharm Sin B, 2024,14(8):3457-3475 （中科院大类1区Top，IF=14.8）

[10] Li H#, Li J#, Zhang Y, Zhao C, Ge J, Sun Y, Fu H*, Li Y*（李英鹏）. The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt/β-catenin signaling pathway. [J].Front Pharmacol, 2024,15:1401979（中科院大类2区，IF=4.4）

[11] Li Y#（李英鹏）, Kong X#, Chu X#, Fu H, Feng X, Zhao C, Deng Y, Ge J*. Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents. [J].Molecules, 2024,29(12) （中科院大类2区，IF=4.2）

[12] Zhi H#, Fu H#, Zhang Y, Fan N, Zhao C, Li Y, Sun Y*, Li Y*（李英鹏）. Progress of cGAS-STING signaling pathway-based modulation of immune response by traditional Chinese medicine in clinical diseases. [J].Front Immunol, 2024,15:1510628（中科院大类2区，IF=5.7）

[13] Fan N#, Zhao F#, Meng Y#, Chen L, Miao L, Wang P, Tang M, Wu X, Li Y*（李英鹏）, Li Y*, Gao Z*. Metal complex lipid-based nanoparticles deliver metabolism-regulating lomitapide to overcome CTC immune evasion via activating STING pathway. [J].Eur J Pharm Biopharm, 2024,203:114467（中科院大类2区，IF=4.4）

[14] Liu J#, Li Y#（李英鹏）, Wang J, Guan B, Chen Z, Liu Z, Xue Y, Li Y, Guan F, Wang Y*. Integrated skin metabolomics and network pharmacology to explore the mechanisms of Goupi Plaster for treating knee osteoarthritis. [J].J Tradit Complement Med, 2024,14(6):675-686（中科院大类3区，IF=3.3）

[15] Feng X#, Ge J#, Fu H#, Miao L, Zhao F, Wang J, Sun Y, Li Y*（李英鹏）, Li Y*. Discovery of small molecule β-catenin suppressors that enhance immunotherapy. [J]. Bioorg Chem, 2023,139:106754（中科院大类2区Top，IF=4.5）

[16] Li Y（李英鹏）, Zhu T, Liang J, Wu Y, Guan X, Liu T, Lü S, Li Y, Wang Y*, Ping Y*. The First Discovery of a Microstructure in Black Plaster and Its Performance Characterization. [J].Drug Des Devel Ther, 2023,17:2223（中科院大类2区，IF=4.7）

[17] Li Y#（李英鹏）, Chu X#, Yin Y#, Li H, Fu H, Feng X, Deng Y, Ge J*. Design, synthesis, and evaluation of 4-(3-(3,5-dimethylisoxazol-4-yl)benzyl)phthalazin-1(2H) -one derivatives: potent BRD4 inhibitors with anti-breast cancer activity. [J].Front Pharmacol, 2023,14:1289003（中科院大类2区，IF=4.4）

[18] Fan N#, Fu H#, Feng X, Chen Y, Wang J, Wu Y, Bian Y*, Li Y*（李英鹏）. Long non-coding RNAs play an important regulatory role in tumorigenesis and tumor progression through aerobic glycolysis. Front Mol Biosci. 2022 Aug 22;9:941653. （中科院大类3区，IF=3.9）

[19] Li Y#（李英鹏）, Liu L#, Shang H, Feng X, Fan N, Wang J, Wu Y, Chen Y, Chu X, Zhong M, Sun Y, Fu H, Huang W*, Li Y*. Self-Assembling Anchorage of Hyaluronic Acid on the Nanoparticle Surface Confers Superiority of Triple Negative Breast Cancer Treatment. Pharmaceutics. 2022 Nov 15;14(11):2461.（中科院大类2区，IF=4.9）

[20]张韫馨, 智慧, 孙玉姣*, 李英鹏*. 纳米医学策略在口服肿瘤疫苗中的应用：从屏障工程到免疫激活[J/OL]. 药学学报, 2025, 1-28.

[21]褚欣虹#, 张瑞萱#, 沈诗阳, 王辉, 孙玉姣, 李英鹏*. 黄芪多糖杂化载体口服中药递药体系的构建及其抗肿瘤应用[J/OL]. 药学学报, 2025, 1-19.

[22] 武毓琦, 王静宇, 陈雅彤, 葛军, 王阳, 孙玉姣*, 李英鹏*. 壳聚糖递药系统在肿瘤光动力治疗中的应用[J]. 化学与生物工程, 2025, 42 (01): 1-8.

[23] 褚欣虹, 刘亮, 钟敏, 孙玉姣, 郭琳, 葛军, 付慧*, 李英鹏*. 姜黄素调控肿瘤干细胞干性的分子机制及研究进展[J]. 中医药学报, 2024, 52 (01): 116-122.

[24] 王静宇, 陈雅彤, 武毓琦, 葛军, 孙玉姣, 付慧*, 李英鹏*. 中药调控乳腺癌干细胞干性的机制研究进展[J]. 中医药学报, 2024, 52 (09): 115-122.

[25] 胡蕊蕊, 付慧, 韩晓燕*, 李英鹏*. 丹参“药对”及制剂对心血管保护的药理作用与临床研究进展[J]. 中医药学报, 2023, 51 (05): 106-110.

[26] 冯旭晨, 武毓琦, 郭琳, 付慧, 王阳, 李英鹏*, 孙玉姣*. 载阿霉素透明质酸聚合物纳米粒的构建及其体外性质研究[J]. 药物评价研究, 2023, 46 (06): 1232

[27] 钟敏,范妮,陈雅彤,孙玉姣,付慧,葛军*,李英鹏*.姜黄素调控非编码RNA抗肿瘤的研究进展[J].现代药物与临床,2023,38(02):467-473.

[28] 陈雅彤,范妮,胡蕊蕊,孙玉姣,付慧*,李英鹏*.姜黄素的免疫调节作用及其肿瘤免疫治疗的研究进展[J].现代药物与临床,2022,37(06):1414-1419.